https://orcid.org/0000-0002-4118-4286
Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Limin Deng & Huiming Jiang. (2023) Decreased Expression of GLYATL1 Predicts Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma. International Journal of General Medicine 16, pages 3757-3768.
Read now
Read now
Michael Serzan & Michael B. Atkins. (2022) Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. Expert Review of Anticancer Therapy 22:6, pages 565-574.
Read now
Read now
Huiming Jiang, Haibin Chen, Pei Wan, Meng Liang & Nanhui Chen. (2021) Upregulation of TMEM45A Promoted the Progression of Clear Cell Renal Cell Carcinoma in vitro. Journal of Inflammation Research 14, pages 6421-6430.
Read now
Read now
Articles from other publishers (18)
Lei Lyu, Rui Min, Fuxin Zheng, Wei Xiang, Tao Huang, Yan Feng, Chuanhua Zhang & Jingdong Yuan. (2024) Prognostic value of inflammation and immune-related gene NOD2 in clear cell renal cell carcinoma. Human Cell.
Crossref
Crossref
Benjamin N. Schmeusser, Dattatraya H. Patil, Edouard H. Nicaise, Manuel Armas‐Phan, Reza Nabavizadeh, Vikram M. Narayan, Shreyas S. Joshi, Kenneth Ogan, Adeboye O. Osunkoya, Mehmet A. Bilen & Viraj A. Master. (2023) 2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race. Cancer 130:3, pages 453-466.
Crossref
Crossref
Keiichiro Mori, Takafumi Yanagisawa, Wataru Fukuokaya, Kosuke Iwatani, Akihiro Matsukawa, Satoshi Katayama, Benjamin Pradere, Ekaterina Laukhtina, Pawel Rajwa, Marco Moschini, Simone Albisinni, Wojciech Krajewski, Alessia Cimadamore, Francesco Del Giudice, Jeremy Teoh, Fumihiko Urabe, Shoji Kimura, Masaya Murakami, Shunsuke Tsuzuki, Jun Miki, Kenta Miki, Shahrokh F. Shariat & Takahiro Kimura. (2023) Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis. International Journal of Urology 31:1, pages 25-31.
Crossref
Crossref
Kai Zeng, Qinyu Li, Guoda Song, Bingliang Chen, Min Luo, Jianping Miao & Bo Liu. (2023) CPT2-mediated fatty acid oxidation inhibits tumorigenesis and enhances sorafenib sensitivity via the ROS/PPARγ/NF-κB pathway in clear cell renal cell carcinoma. Cellular Signalling 110, pages 110838.
Crossref
Crossref
Linjun Zhou, Weidong Zhou, Yuan Li & Ruifang Hua. (2023) m1A Regulatory gene signatures are associated with certain immune cell compositions of the tumor microenvironment and predict survival in kidney renal clear cell carcinoma. European Journal of Medical Research 28:1.
Crossref
Crossref
Jie Yang, Gang Li, Yue'e Huang & Ying Liu. (2023) Decreasing expression of Prohibitin-2 lowers the oncogenicity of renal cell carcinoma cells by suppressing eIF4E-mediated oncogene translation via MNK inhibition. Toxicology and Applied Pharmacology 466, pages 116458.
Crossref
Crossref
Harshit Garg, Philip Whalen, Haneen Marji, Robert Cooper, Furkan Dursun, Mukund Bhandari, Lokesh Khanna, Lalithapriya Jayakumar, Michael A. Liss, Robert S. Svatek, Ronald Rodriguez, Dharam Kaushik & Deepak K. Pruthi. (2023) Patency outcomes of primary inferior vena cava repair in radical nephrectomy and tumor thrombectomy. Journal of Vascular Surgery: Venous and Lymphatic Disorders 11:3, pages 595-604.e2.
Crossref
Crossref
Robert J Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Zurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C Goh, Dingwei Ye, Alejo Lingua, Jean-Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey Sosman, Michael Staehler, Sergio Vázquez Estévez, Burcin Simsek, Julia Spiridigliozzi, Aleksander Chudnovsky & Axel Bex. (2023) Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. The Lancet 401:10379, pages 821-832.
Crossref
Crossref
Federica Cosso, Giandomenico Roviello, Gabriella Nesi, Sonia Shabani, Pietro Spatafora, Donata Villari & Martina Catalano. (2023) Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?. International Journal of Molecular Sciences 24:4, pages 4243.
Crossref
Crossref
Kai Zeng, Guoda Song, Bingliang Chen, Xintao Gao, Chaofan Liu, Jianping Miao, Yajun Ruan, Yang Luan, Xin Chen, Jihong Liu, Qinyu Li & Bo Liu. (2022) Comprehensive analysis to identify the RP11–478C19.2/ E2F7 axis as a novel biomarker for treatment decisions in clear cell renal cell carcinoma. Translational Oncology 25, pages 101525.
Crossref
Crossref
Hye Won Lee, Hee Seung Seo, Seon-Yong Yeom, Se-Na Kim, Cho Rim Kim, Dae-Hwan Park, Wooram Park, Young Bin Choy, Chun Gwon Park & Seong Il Seo. (2022) Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma. International Journal of Molecular Sciences 23:20, pages 12634.
Crossref
Crossref
Qinyu Li, Xueyan Xiao, Bingliang Chen, Guoda Song, Kai Zeng, Beining Li, Jianping Miao, Chaofan Liu, Yang Luan & Bo Liu. (2022) A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma. Frontiers in Oncology 12.
Crossref
Crossref
Zhiping Chen, Mengting Zhang, Yukang Lu, Tao Ding, Zhanyu Liu, Yanmei Liu, Zhaoling Zhou & Lanfeng Wang. (2022) Overexpressed lncRNA FTX promotes the cell viability, proliferation, migration and invasion of renal cell carcinoma via FTX/miR‑4429/UBE2C axis. Oncology Reports 48:3.
Crossref
Crossref
Gangcheng Liu, Donglan Xiong, Zhifei Che, Hualei Chen & Wenyi Jin. (2022) A novel inflammation‑associated prognostic signature for clear cell renal cell carcinoma. Oncology Letters 24:3.
Crossref
Crossref
Nóra Ördög, Barbara N Borsos, Hajnalka Majoros, Zsuzsanna Ujfaludi, Gabriella Pankotai-Bodó, Sarolta Bankó, Farkas Sükösd, Levente Kuthi & Tibor Pankotai. (2022) The clinical significance of epigenetic and RNAPII variabilities occurring in clear cell renal cell carcinoma as a potential prognostic marker. Translational Oncology 20, pages 101420.
Crossref
Crossref
Antonio Matrone, Carla Gambale, Alessandro Prete & Rossella Elisei. (2022) Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine. Frontiers in Endocrinology 13.
Crossref
Crossref
Li Tao, Huiyun Zhang, Guangyu An, Haoning Lan, Yaoqi Xu, Yang Ge & Jiannan Yao. (2021) Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology 11.
Crossref
Crossref
Teele Kuusk, Yasmin Abu-Ghanem, Faiz Mumtaz, Thomas Powles & Axel Bex. (2021) Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. Current Opinion in Urology 31:3, pages 262-269.
Crossref
Crossref